SIGC Antibody

Overview of Siglec Antibodies

Siglec antibodies target a family of immunomodulatory receptors involved in glycan recognition and immune regulation. These antibodies are engineered to either block inhibitory signaling or enhance immune cell activation, particularly in cancer and autoimmune diseases .

Table 1: Comparative Features of Siglec-Targeting Antibodies

Research Advancements and Data Highlights

• Anti-Siglec-9 Antibodies:

  • 8A1E9 Clone: Demonstrated 2.5-fold higher CD107a degranulation in NK cells compared to controls, indicating enhanced cytotoxicity .

  • Selectivity: No cross-reactivity with Siglec-7 or Siglec-3, ensuring precise targeting .

  • In Vivo Efficacy: Reduced ovarian cancer tumor volume by 60% in humanized mouse models .

• Anti-Siglec-10 Antibodies:

  • ONC-841: Part of OncoC4’s pipeline; phase I trials initiated in 2024 to assess safety in solid tumors .

  • Multi-Specific Approaches: Includes bispecific antibodies (ONC-783) and CAR-T therapies (ONC-782) targeting Siglec-10 .

• SIgA Structural Biology:

  • Cryo-EM structures reveal asymmetric binding of secretory component (SC) to dimeric IgA, enabling pathogen neutralization without inflammatory cascades .

Challenges and Future Directions

• Specificity Concerns: Siglec-9 shares 84% homology with Siglec-7, necessitating high-affinity antibodies to avoid off-target effects .

• Combination Therapies: Synergy with PD-1/CTLA-4 inhibitors under investigation to overcome resistance .

• Clinical Translation: Early-phase trials for Siglec-9/10 antibodies face hurdles in biomarker identification and dosing optimization .